Candriam S.C.A. Acquires 10,439 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Candriam S.C.A. boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,395 shares of the company’s stock after purchasing an additional 10,439 shares during the quarter. Candriam S.C.A.’s holdings in Dyne Therapeutics were worth $9,457,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 3rd quarter worth approximately $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares during the period. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the period. Finally, Quest Partners LLC lifted its position in shares of Dyne Therapeutics by 898.3% in the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after acquiring an additional 3,090 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,387 shares of company stock worth $142,789. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

DYN stock opened at $12.40 on Friday. The business has a fifty day moving average price of $16.03 and a 200 day moving average price of $26.82. Dyne Therapeutics, Inc. has a fifty-two week low of $11.62 and a fifty-two week high of $47.45. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -3.48 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the subject of a number of research reports. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, February 28th. Scotiabank started coverage on Dyne Therapeutics in a report on Friday. They issued a “sector outperform” rating and a $50.00 target price for the company. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright dropped their target price on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.75.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.